QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.37 Million SEK | -21.53% |
| 2022 | 5.57 Million SEK | 2480.56% |
| 2021 | 216 Thousand SEK | -88.39% |
| 2020 | 1.86 Million SEK | -58.33% |
| 2019 | 4.46 Million SEK | 32.25% |
| 2018 | 3.37 Million SEK | -14.11% |
| 2017 | 3.93 Million SEK | 329.26% |
| 2016 | 916 Thousand SEK | -93.64% |
| 2015 | 14.4 Million SEK | 55.37% |
| 2014 | 9.26 Million SEK | -29.02% |
| 2013 | 13.05 Million SEK | 34.68% |
| 2012 | 9.69 Million SEK | -23.67% |
| 2011 | 12.7 Million SEK | 31.21% |
| 2010 | 9.68 Million SEK | -5.36% |
| 2009 | 10.22 Million SEK | 11.54% |
| 2008 | 9.17 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.18 Million SEK | 0.0% |
| 2024 Q1 | 1.18 Million SEK | -10.37% |
| 2023 Q4 | 1.31 Million SEK | 0.0% |
| 2023 Q1 | 870.5 Thousand SEK | -34.94% |
| 2023 FY | 4.37 Million SEK | -21.53% |
| 2023 Q2 | 870.5 Thousand SEK | 0.0% |
| 2023 Q3 | 1.31 Million SEK | 51.23% |
| 2022 FY | 5.57 Million SEK | 2480.56% |
| 2022 Q1 | 1.14 Million SEK | 627.78% |
| 2022 Q2 | 1.45 Million SEK | 27.37% |
| 2022 Q4 | 1.33 Million SEK | -18.61% |
| 2022 Q3 | 1.64 Million SEK | 13.22% |
| 2021 Q2 | 2.58 Million SEK | 3.65% |
| 2021 FY | 216 Thousand SEK | -88.39% |
| 2021 Q4 | -216 Thousand SEK | -200.0% |
| 2021 Q1 | 2.49 Million SEK | 376.1% |
| 2021 Q3 | 216 Thousand SEK | -91.63% |
| 2020 Q3 | 595 Thousand SEK | -68.03% |
| 2020 Q2 | 1.86 Million SEK | 4035.56% |
| 2020 FY | 1.86 Million SEK | -58.33% |
| 2020 Q1 | 45 Thousand SEK | -97.29% |
| 2020 Q4 | 523 Thousand SEK | -12.1% |
| 2019 FY | 4.46 Million SEK | 32.25% |
| 2019 Q2 | 1.48 Million SEK | 663.59% |
| 2019 Q1 | 195 Thousand SEK | 112.4% |
| 2019 Q4 | 1.66 Million SEK | 47.95% |
| 2019 Q3 | 1.12 Million SEK | -24.65% |
| 2018 Q1 | 1.02 Million SEK | -64.71% |
| 2018 FY | 3.37 Million SEK | -14.11% |
| 2018 Q4 | -1.57 Million SEK | -207.67% |
| 2018 Q3 | 1.46 Million SEK | -40.67% |
| 2018 Q2 | 2.46 Million SEK | 139.4% |
| 2017 FY | 3.93 Million SEK | 329.26% |
| 2017 Q2 | 608 Thousand SEK | 100.0% |
| 2017 Q3 | 411 Thousand SEK | -32.4% |
| 2017 Q4 | 2.91 Million SEK | 608.76% |
| 2017 Q1 | 304 Thousand SEK | 103.61% |
| 2016 Q1 | 2.7 Million SEK | 7.99% |
| 2016 FY | 916 Thousand SEK | -93.64% |
| 2016 Q3 | 3.33 Million SEK | 0.73% |
| 2016 Q4 | -8.42 Million SEK | -352.9% |
| 2016 Q2 | 3.3 Million SEK | 22.39% |
| 2015 Q1 | 5.09 Million SEK | 152.61% |
| 2015 Q2 | 3.06 Million SEK | -39.84% |
| 2015 Q4 | 2.5 Million SEK | -33.21% |
| 2015 FY | 14.4 Million SEK | 55.37% |
| 2015 Q3 | 3.74 Million SEK | 22.34% |
| 2014 Q1 | 3.25 Million SEK | 18.5% |
| 2014 FY | 9.26 Million SEK | -29.02% |
| 2014 Q4 | 2.01 Million SEK | 15.61% |
| 2014 Q3 | 1.74 Million SEK | -22.74% |
| 2014 Q2 | 2.25 Million SEK | -30.67% |
| 2013 FY | 13.05 Million SEK | 34.68% |
| 2013 Q4 | 2.74 Million SEK | -41.12% |
| 2013 Q1 | 2.9 Million SEK | 89.57% |
| 2013 Q2 | 2.73 Million SEK | -5.81% |
| 2013 Q3 | 4.66 Million SEK | 70.28% |
| 2012 Q3 | 2.02 Million SEK | 0.0% |
| 2012 Q4 | 1.53 Million SEK | -24.28% |
| 2012 FY | 9.69 Million SEK | -23.67% |
| 2011 Q2 | 2.91 Million SEK | 0.0% |
| 2011 FY | 12.7 Million SEK | 31.21% |
| 2010 Q2 | 2.71 Million SEK | 0.0% |
| 2010 FY | 9.68 Million SEK | -5.36% |
| 2009 Q2 | 2.5 Million SEK | 0.0% |
| 2009 FY | 10.22 Million SEK | 11.54% |
| 2008 FY | 9.17 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 92.473% |
| Ziccum AB (publ) | 3.74 Million SEK | -16.733% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.29% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 91.336% |
| Mendus AB (publ) | 28.48 Million SEK | 84.646% |
| Genovis AB (publ.) | 158.23 Million SEK | 97.236% |
| Intervacc AB (publ) | 8.01 Million SEK | 45.427% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 97.434% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 90.036% |
| Aptahem AB (publ) | 2.63 Million SEK | -66.271% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -322.609% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -5580.519% |
| Fluicell AB (publ) | 3.33 Million SEK | -31.037% |
| Saniona AB (publ) | 16.84 Million SEK | 74.026% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 73.341% |
| Biovica International AB (publ) | 7.29 Million SEK | 40.0% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -263.591% |
| AcouSort AB (publ) | 10.55 Million SEK | 58.544% |
| Xintela AB (publ) | 78 Thousand SEK | -5507.692% |
| Abliva AB (publ) | 137 Thousand SEK | -3092.701% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 92.406% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -117.18% |
| OncoZenge AB (publ) | 3000.00 SEK | -145700.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -2721.935% |
| CombiGene AB (publ) | 5.54 Million SEK | 21.106% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.638% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.745% |
| Corline Biomedical AB | 25.03 Million SEK | 82.525% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 22.966% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -506.657% |
| I-Tech AB | 120.86 Million SEK | 96.381% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 96.738% |
| Cyxone AB (publ) | 5.14 Million SEK | 15.035% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 37.957% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 58.986% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 61.051% |
| Nanologica AB (publ) | 1.44 Million SEK | -203.119% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -8152.83% |
| BioInvent International AB (publ) | 71.46 Million SEK | 93.879% |
| Alzinova AB (publ) | 270 Thousand SEK | -1520.0% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 87.581% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -198.971% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -54.996% |
| Simris Alg AB (publ) | 4.35 Million SEK | -0.459% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -3264.615% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 98.168% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -18917.391% |